FDA hopes to issue a draft guidance on co-development of drugs and diagnostics by “late summer,” according to Elizabeth Mansfield, the top personalized medicine official at CDRH.
The planned guidance is a follow-up effort to draft guidelines released last July providing FDA’s definition of a companion diagnostic and outlining policies for approval and labeling of therapeutic/diagnostic pairs....